血清肿瘤标志物检测在卵巢癌诊断中的临床意义(1)
[摘要] 目的 探讨血清肿瘤标志物检测在卵巢癌诊断中的临床意义。 方法 选择2016年2月～2018年2月收治的50例卵巢癌患者为观察组，同时选择同期进行手术治疗确诊为单纯良性卵巢囊肿50例患者为良性肿瘤组，选择同期进行体检的正常50例女性为对照组，对血清肿瘤标志物(CA125、CA199、CEA、CA153、AFP和β-HCG)进行检测，判断诊断效果。 结果 观察组的CA125、CA199、CEA、CA153、AFP和β-HCG含量与良性肿瘤组、对照组对比差异有统计学意义(t=6.382、8.938、9.382、10.492、9.824、8.842、6.482、5.202、7.234、5.291、6.435、9.424，P<0.05)。良性腫瘤组与对照组对比差异也有统计学意义(t=6.094、6.382、9.482、7.973、9.498、10.421，P<0.05)。将观察组及良性肿瘤组患者进行ROC曲线分析，其中曲线下面积A分别为0.823、0.728、0.669、0.602、0.570及0.500。结论 CA125、CA199、CEA、CA153、AFP及β-HCG指标对于卵巢癌疾病的早期诊断具有临床应用价值。对于肿瘤标志物进行检测时，应该联合临床特征，尤其是联合影像检查方式及病理组织学等方式，应该综合观察，正确判断。
[关键词] 血清肿瘤标志物;卵巢癌;CA125;CA199
[中图分类号] R737.31 [文献标识码] B [文章编号] 1673-9701(2019)03-0112-03
[Abstract] Objective To explore the clinical significance of serum tumor marker detection in the diagnosis of ovarian cancer. Methods 50 patients with ovarian cancer who were admitted from February 2016 to February 2018 were enrolled in the observation group. Meanwhile， 50 patients with benign ovarian cysts were selected as the benign tumor group. 50 healthy women who underwent physical examination at the same time were selected as the control group. The serum tumor markers(CA125， CA199， CEA， CA153， AFP and β-HCG) were tested to determine the diagnostic effect. Results The contents of CA125， CA199， CEA， CA153， AFP and β-HCG in the observation group were significantly different from those in the benign tumor group and the control group(t=6.382， 8.938， 9.382， 10.492， 9.824， 8.842， 6.482， 5.202， 7.234， 5.291， 6.435， 9.424， P<0.05). There was also a statistically significant difference between the benign tumor group and the control group(t=6.094， 6.382， 9.482， 7.973， 9.498， 10.421， P<0.05). The ROC curve analysis was performed on the observation group and the benign tumor group， wherein the area under the curve was 0.823， 0.728， 0.669， 0.602， 0.570 and 0.500， respectively. Conclusion CA125， CA199， CEA， CA153， AFP and β-HCG have clinical application value for the early diagnosis of ovarian cancer diseases. For the detection of tumor markers， clinical features should be combined， especially imaging and pathological histology， which should be comprehensively observed and correctly judged.
[Key words] Serum tumor marker; Ovarian cancer; CA125; CA199
卵巢癌是一种多发妇科恶性肿瘤[1-2]。该疾病的特点是死亡率高、早期诊断难度大、复发率高等特点。临床研究表明，卵巢癌患者早期发现、及时治疗后，绝大部分患者一般会生存5年以上的时间，但对于晚期卵巢癌患者，仅30%的患者会生存5年以上[3，4]。因此，对卵巢癌患者进行早期诊断，是治疗及预后的关键。对卵巢癌进行早期诊断时，常通过肿瘤标志物进行研究。在本次研究中，对卵巢癌患者血清肿瘤标志物进行检测，为临床对卵巢癌早期诊断提供参考，现报道如下。, 百拇医药(李国英 阿孜亚 张文宇 等)
[关键词] 血清肿瘤标志物;卵巢癌;CA125;CA199
[中图分类号] R737.31 [文献标识码] B [文章编号] 1673-9701(2019)03-0112-03
[Abstract] Objective To explore the clinical significance of serum tumor marker detection in the diagnosis of ovarian cancer. Methods 50 patients with ovarian cancer who were admitted from February 2016 to February 2018 were enrolled in the observation group. Meanwhile， 50 patients with benign ovarian cysts were selected as the benign tumor group. 50 healthy women who underwent physical examination at the same time were selected as the control group. The serum tumor markers(CA125， CA199， CEA， CA153， AFP and β-HCG) were tested to determine the diagnostic effect. Results The contents of CA125， CA199， CEA， CA153， AFP and β-HCG in the observation group were significantly different from those in the benign tumor group and the control group(t=6.382， 8.938， 9.382， 10.492， 9.824， 8.842， 6.482， 5.202， 7.234， 5.291， 6.435， 9.424， P<0.05). There was also a statistically significant difference between the benign tumor group and the control group(t=6.094， 6.382， 9.482， 7.973， 9.498， 10.421， P<0.05). The ROC curve analysis was performed on the observation group and the benign tumor group， wherein the area under the curve was 0.823， 0.728， 0.669， 0.602， 0.570 and 0.500， respectively. Conclusion CA125， CA199， CEA， CA153， AFP and β-HCG have clinical application value for the early diagnosis of ovarian cancer diseases. For the detection of tumor markers， clinical features should be combined， especially imaging and pathological histology， which should be comprehensively observed and correctly judged.
[Key words] Serum tumor marker; Ovarian cancer; CA125; CA199
卵巢癌是一种多发妇科恶性肿瘤[1-2]。该疾病的特点是死亡率高、早期诊断难度大、复发率高等特点。临床研究表明，卵巢癌患者早期发现、及时治疗后，绝大部分患者一般会生存5年以上的时间，但对于晚期卵巢癌患者，仅30%的患者会生存5年以上[3，4]。因此，对卵巢癌患者进行早期诊断，是治疗及预后的关键。对卵巢癌进行早期诊断时，常通过肿瘤标志物进行研究。在本次研究中，对卵巢癌患者血清肿瘤标志物进行检测，为临床对卵巢癌早期诊断提供参考，现报道如下。, 百拇医药(李国英 阿孜亚 张文宇 等)